• DOI:10.1016/S0140-6736(07)61165-9
Corpus ID: 1420863

Chronic myeloid leukaemia

@article{Hehlmann2007ChronicML,
  title={Chronic myeloid leukaemia},
  author={Ruediger Hehlmann and A. Hochhaus and M. Baccarani and on behalf of the European LeukemiaNet},
  journal={The Lancet},
  year={2007},
  volume={370},
  pages={342-350}
}

Ruediger Hehlmann, A. Hochhaus, +1 author on behalf of the European LeukemiaNet

Published 2007

Medicine

The Lancet

Chronic myeloid leukaemia (CML) was the first neoplastic disease for which knowledge of the genotype led to a rationally designed therapy. As a result of its well known pathophysiology, straightforward diagnosis, well established prognostic factors, and treatment for the cause of disease, CML has been studied to an extent that far exceeds that expected from its frequency, and serves as a model disease for other cancers. Imatinib, an inhibitor of BCR-ABL tyrosine kinase, has revolutionised… CONTINUE READING

View on Elsevier

doi.org

Save to Library

Create Alert

Cite

Launch Research Feed